Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
extended the action date for the supplemental Biologics License
Application (sBLA) for KEYTRUDA®(pembrolizumab), the
company ’s anti-PD-1 therapy, for previously treated patients with
advanced microsatellite instability-high (MSI-H) cancer. The company
recently submitted additional data and analyses to the FDA related to
the pending application.Language:
EnglishContact: MerckMedia:Pamela Eisele, [phone]orKim Hamilton, [phone]orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, [phone]Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more

Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news